相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality
Trevor J. Orchard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study
Yuhao Huang et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study
A. C. Shore et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Excess Body Mass Index- and Waist Circumference-Years and Incident Cardiovascular Disease: The CARDIA Study
Jared P. Reis et al.
OBESITY (2015)
Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus
Benli Su et al.
JOURNAL OF DIABETES (2015)
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Anoop Dinesh Shah et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
Eun Young Lee et al.
JOURNAL OF ENDOCRINOLOGY (2015)
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Rury R. Holman et al.
AMERICAN HEART JOURNAL (2014)
Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications
Paul J. Beisswenger
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Residual macrovascular risk in 2013: what have we learned?
Jean-Charles Fruchart et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
John M. Lachin et al.
DIABETES CARE (2014)
Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study
C. Ll Morgan et al.
DIABETES OBESITY & METABOLISM (2014)
Mortality risk with sulphonylureas compared to metformin
S. E. Holden et al.
DIABETES OBESITY & METABOLISM (2014)
Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Greg L. Plosker
DRUGS (2014)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
The Disposition Index Does Not Reflect β-Cell Function in IGT Subjects Treated With Pioglitazone
Ralph A. DeFronzo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
Vivian A. Fonseca et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial
Hertzel C. Gerstein et al.
LANCET (2014)
The Target of Metformin in Type 2 Diabetes
Ele Ferrannini
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial
David Preiss et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and alzheimer's disease
Enrique Blazquez et al.
FRONTIERS IN ENDOCRINOLOGY (2014)
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Kenneth W. Mahaffey et al.
AMERICAN HEART JOURNAL (2013)
Insulin Sensitivity and Carotid Intima-Media Thickness Relationship Between Insulin Sensitivity and Cardiovascular Risk Study
Michaela Kozakova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Clifford J. Bailey et al.
BMC MEDICINE (2013)
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Samuel S. Engel et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes
Junichi Matsubara et al.
CIRCULATION JOURNAL (2013)
Prevention of Diabetes With Pioglitazone in ACT NOW Physiologic Correlates
Ralph A. DeFronzo et al.
DIABETES (2013)
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
Julio Rosenstock et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)
Eva M. Lonn et al.
DIABETES CARE (2013)
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
In Vivo Actions of Peroxisome Proliferator-Activated Receptors Glycemic control, insulin sensitivity, and insulin secretion
Roy Eldor et al.
DIABETES CARE (2013)
Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes Systematic review and meta-analysis of clinical studies
Salvatore Calanna et al.
DIABETES CARE (2013)
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
W. B. White et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus
Yi-Chih Hung et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2013)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Linda G. Mellbin et al.
EUROPEAN HEART JOURNAL (2013)
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
William N. Washburn et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
Craig J. Currie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Insulin resistance in the vasculature
Kieren J. Mather et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study
Anna Solini et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of Dapagliflozin on Cardiovascular Risk Factors
Agata Ptaszynska et al.
POSTGRADUATE MEDICINE (2013)
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study
D. T. Eurich et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Michael E. Cobble et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Odd Erik Johansen et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III Trial
Chris P. H. Lexis et al.
CARDIOVASCULAR DRUGS AND THERAPY (2012)
Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
Sarah Farr et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
A. J. Scheen
DIABETES & METABOLISM (2012)
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
D. Nathanson et al.
DIABETOLOGIA (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Jacob Lonborg et al.
EUROPEAN HEART JOURNAL (2012)
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
Philip A. Read et al.
HEART (2012)
What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes
Christopher Ll Morgan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury
Veerle Matheeussen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Christine Clar et al.
BMJ OPEN (2012)
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
Thomas Karagiannis et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide-1-Based Therapies
Robert Chilton et al.
AMERICAN JOURNAL OF MEDICINE (2011)
The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury
Yumei Ye et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
Markolf Hanefeld et al.
CARDIOVASCULAR DIABETOLOGY (2011)
A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans
Philip A. Read et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2011)
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies
Steven P. Marso et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
A1C and Cardiovascular Outcomes in Type 2 Diabetes A nested case-control study
Danielle C. Colayco et al.
DIABETES CARE (2011)
Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
Jennie H. Best et al.
DIABETES CARE (2011)
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
Pleun C. M. van Poppel et al.
DIABETES CARE (2011)
Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
Mathijs C. Bunck et al.
DIABETES CARE (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?
K. L. Rensing et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
A. J. Tremblay et al.
DIABETES OBESITY & METABOLISM (2011)
An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
S. Madsbad et al.
DIABETES OBESITY & METABOLISM (2011)
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M. A. Nauck et al.
DIABETOLOGIA (2011)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Tina Ken Schramm et al.
EUROPEAN HEART JOURNAL (2011)
Number of Coronary Heart Disease Risk Factors and Mortality in Patients With First Myocardial Infarction
John G. Canto et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Preservation of β-Cell Function: The Key to Diabetes Prevention
Ralph A. DeFronzo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients Insights From the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study
Stephen J. Nicholls et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Pathophysiology of Prediabetes
Ele Ferrannini et al.
MEDICAL CLINICS OF NORTH AMERICA (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Ted Okerson et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Mads Halbirk et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis
Ronan Roussel et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
Eric A. Schwartz et al.
ATHEROSCLEROSIS (2010)
Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study
Casper H. Jorgensen et al.
CARDIOVASCULAR DIABETOLOGY (2010)
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy A retrospective analysis
Kevin M. Pantalone et al.
DIABETES CARE (2010)
Hypoglycemia, Diabetes, and Cardiovascular Events
Cyrus V. Desouza et al.
DIABETES CARE (2010)
Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study
B. Sillars et al.
DIABETES OBESITY & METABOLISM (2010)
Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?
G. Schernthaner et al.
DIABETES OBESITY & METABOLISM (2010)
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study
J. -M. Gamble et al.
DIABETES OBESITY & METABOLISM (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
Exenatide Versus Glibenclamide in Patients with Diabetes
G. Derosa et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
R. A. DeFronzo
DIABETOLOGIA (2010)
Efficacy of α-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia
W. LEONHARDT et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome
Edwin K. Jackson
HYPERTENSION (2010)
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Craig J. Currie et al.
LANCET (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
Giuseppe Derosa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Robert Frederich et al.
POSTGRADUATE MEDICINE (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
Amalia Gastaldelli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Impact of peripheral arterial disease in patients with diabetes-Results from PROactive (PROactive 11)
J. A. Dormandy et al.
ATHEROSCLEROSIS (2009)
Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
Le Thi Kim Chung et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
David J. Grieve et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
J. Jendle et al.
DIABETES OBESITY & METABOLISM (2009)
Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Mykola Khalangot et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
P. V. Hojberg et al.
DIABETOLOGIA (2009)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull et al.
DIABETOLOGIA (2009)
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
G. Schernthaner
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
Hongbin Liu et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?
Alberto Zanchetti
JOURNAL OF HYPERTENSION (2009)
CNTO736, a Novel Glucagon-Like Peptide-1 Receptor Agonist, Ameliorates Insulin Resistance and Inhibits Very Low-Density Lipoprotein Production in High-Fat-Fed Mice
Edwin T. Parlevliet et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The incretin system and its role in type 2 diabetes mellitus
Jens Juul Holst et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo
Dawn K. Coletta et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence - The Multi-Ethnic Study of Atherosclerosis (MESA)
Aaron R. Folsom et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic Review
Elizabeth Selvin et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose:: Results of a 15 years follow-up in a Mediterranean population
Davide Noto et al.
ATHEROSCLEROSIS (2008)
Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of Pioglitazone
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2008)
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus
Michael Davidson et al.
CIRCULATION (2008)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat
Indu Poornima et al.
CIRCULATION-HEART FAILURE (2008)
Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome:: The mefisto study
Eduardo Meaney et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes Epidemiology and risk factors
Carlo B. Giorda et al.
DIABETES CARE (2008)
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
J. -P. Courreges et al.
DIABETIC MEDICINE (2008)
Evidence-based medication and revascularization:: powerful tools in the management of patients with diabetes and coronary artery disease:: a report from the Euro Heart Survey on diabetes and the heart
Matteo Anselmino et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2008)
Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes
Kaspar Berneis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease
Christian A. Schneider et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression
Hongbin Liu et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
B. Richter et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2008)
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
Ananda Basu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic β-cell death in the chronic phase
Akira Takahashi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-retated mortality
M. Monami et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Insulin resistance, insulin response, and obesity as indicators of metabolic risk
Ele Ferrannini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Incidence of coronary heart disease in type 2 diabetic men and women - Impact of microvascular complications, treatment, and geographic location
Angelo Avogaro et al.
DIABETES CARE (2007)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction - Results from the PROactive (PROactive 05) study
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin
Giuseppe Derosa et al.
HYPERTENSION RESEARCH (2007)
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke - Results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)
Robert Wilcox et al.
STROKE (2007)
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Amalia Gastaldelli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population - The Bruneck study
Enzo Bonora et al.
DIABETES CARE (2007)
Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes
A. Gastaldelli et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
The role of gut hormones in glucose homeostasis
Daniel J. Drucker
JOURNAL OF CLINICAL INVESTIGATION (2007)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease:: a report from the Euro Heart Survey on diabetes and the heart
Mattie Lenzen et al.
EUROPEAN HEART JOURNAL (2006)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The effect of pioglitazone on the liver - Role of adiponectin
Amalia Gastaldelli et al.
DIABETES CARE (2006)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study
Gillian L. Booth et al.
LANCET (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
The effects of thiazolidinediones on blood pressure levels - A systematic review
Pantelis A. Sarafidis et al.
BLOOD PRESSURE (2006)
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
JMM Evans et al.
DIABETOLOGIA (2006)
The place of sulfonylureas in the therapy for type 2 diabetes mellitus
S Del Prato et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review
A Natali et al.
DIABETOLOGIA (2006)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
DM Lloyd-Jones et al.
CIRCULATION (2006)
Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes
AH Xiang et al.
DIABETES (2006)
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
SH Simpson et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes
FMAC Martens et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Mechanisms of β-cell death in type 2 diabetes
MY Donath et al.
DIABETES (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Dose-response effect of elevated plasma free fatty acid on insulin signaling
R Belfort et al.
DIABETES (2005)
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus -: Results from a controlled randomized study
MR Langenfeld et al.
CIRCULATION (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Metabolic syndrome: Evaluation of pathological and therapeutic outcomes
PJ Miranda et al.
AMERICAN HEART JOURNAL (2005)
Sulfonylurea induced beta-cell apoptosis in cultured human islets
K Maedler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis
E Ferrannini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach
H Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus
F Abbasi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
AS Go et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Extrapancreatic effects of GIP and GLP-1
A Vella et al.
HORMONE AND METABOLIC RESEARCH (2004)
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
A Gastaldelli et al.
DIABETOLOGIA (2004)
Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes
N Katakami et al.
DIABETOLOGIA (2004)
Vascular effects of improving metabolic control with melformin or rosiglitazone in type 2 diabetes
A Natali et al.
DIABETES CARE (2004)
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes
K Matsumoto et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Relation of Metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention
J Kao et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
JP Gutzwiller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Repaglinide - A pharmacoeconomic review of its use in type 2 diabetes mellitus
GL Plosker et al.
PHARMACOECONOMICS (2004)
Insulin resistance and the effects of thiazolidinediones on cardiac metabolism
LH Young
AMERICAN JOURNAL OF MEDICINE (2003)
Thiazolidinediones and blood lipids in type 2 diabetes
JPH van Wijk et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes
S Kashyap et al.
DIABETES (2003)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
JL Chiasson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin
G Derosa et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2003)
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
M Kavianipour et al.
PEPTIDES (2003)
Impairment of myocardial protection in type 2 diabetic patients
TM Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors
G Derosa et al.
CLINICAL THERAPEUTICS (2003)
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes
JA Johnson et al.
DIABETES CARE (2002)
Fasting and postchallenge glycemia and cardiovascular disease risk - The framingham offspring study
JB Meigs et al.
DIABETES CARE (2002)
Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis - The Atherosclerosis Risk in Communities Study
SH Golden et al.
DIABETES (2002)
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals
M Matsuda et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects - Prospective data from the Verona Diabetes Complicated Study
E Bonora et al.
DIABETES CARE (2002)
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease - The San Antonio Heart Study
AJG Hanley et al.
DIABETES CARE (2002)
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
JL Chiasson et al.
LANCET (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
WC Knowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide
A Holstein et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2001)
Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
NJ Morrish et al.
DIABETOLOGIA (2001)
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study
S Madsbad et al.
DIABETIC MEDICINE (2001)
β-cell mass dynamics in Zucker diabetic fatty rats -: Rosiglitazone prevents the rise in net cell death
DT Finegood et al.
DIABETES (2001)
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
Y Miyazaki et al.
DIABETES CARE (2001)
Cardiovascular morbidity and mortality associated with the metabolic syndrome
B Isomaa et al.
DIABETES CARE (2001)
Glucose tolerance and cardiovascular mortality -: Comparison of fasting and 2-hour diagnostic criteria
K Borch-Johnsen et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden
B Hedblad et al.
DIABETIC MEDICINE (2000)
Treatment of familial hypertriglyceridaemia with acarbose
M Malaguarnera et al.
DIABETES OBESITY & METABOLISM (2000)
Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study
S Halimi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2000)
分享论文
